OXFORD UNIVERSITY PRESS

QJM: An International Journal of Medicine

ONCOGENIC OSTEOMALACIA

Journal:	QJM: An International Journal of Medicine
Manuscript ID	QJM-2017-1043
Manuscript Type:	Clinical Picture
Date Submitted by the Author:	29-Dec-2017
Complete List of Authors:	Annamalai, Anand; Ashwin Speciality Hospital, Endocrinology and Diabetes Gill, Anthony; Royal North Shore Hospital, Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, University of Sydney, and NSW Health Pathology, Department of Anatomical Pathology Shinto, Ajit; Kovai Medical Centre Hospital, Department of Nuclear Medicine Sivakumar, R; Preethi Hospital, Department of Orthopaedics Singhi, Prahlad Kumar; Preethi Hospital, Department of Orthopaedics Prabhu, V A; Ashwin Speciality Hospital, Department of Orthopaedics Sridhar, Subbiah; Madurai Medical College, Endocrinology Shanthi, Radhakrishnan; Aravind Eye Care Hospitals, Department of Pathology Puri, Vipla; PD Hinduja National Hospital and Medical Research Centre, Department of Laboratory Medicine Gururaj, N; CSI College of Research and Dental Sciences, Oral Pathology Gopalakrishnan, Chandrasekhar ; Ashwin Speciality Hospital, Department of Surgery Chelian, Mathirajan; Ashwin Speciality Hospital, Department of Surgery and Anaesthesia Srinivasan, Kaliappan; KGS Scan Centre, Radiology Clifton-Bligh, Roderick ; Royal North Shore Hospital, Department of Endocrinology Gurnell, Mark; Institute of Metabolic Science, Addenbrooke's Hospital, Endocrinology
Keywords:	Endocrinology, Biochemistry & metabolism, Musculoskeletal disease, Imaging, Medical practice
	·

SCHOLARONE[™] Manuscripts

ONCOGENIC OSTEOMALACIA

Anand K Annamalai¹, Anthony J Gill², Ajit Shinto³, R Sivakumar⁴, Prahlad Kumar Singhi⁴, V.A. Prabhu⁵, Subbiah Sridhar⁶, Radhakrishnan Shanthi⁷, Vipla Puri⁸, N Gururaj⁹, Chandrasekhar Gopalakrishnan⁵, Mathirajan Chelian⁵, K.G. Srinivasan¹⁰, Roderick Clifton-Bligh¹¹, Mark Gurnell¹²

¹Department of Endocrinology, Ashwin Speciality Hospital, Madurai, Tamil Nadu, India; ²Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, University of Sydney, and NSW Health Pathology, Department of Anatomical Pathology Royal North Shore Hospital, Australia; ³Department of Nuclear Medicine, Kovai Medical Centre Hospital, Coimbatore, India; ⁴Department of Orthopaedics, Preethi Hospital, Madurai, India; ⁵Department of Surgery and Anaesthesiology, Ashwin Speciality Hospital, Madurai, Tamil Nadu, India; ⁶Department of Endocrinology, Madurai Medical College, Tamil Nadu, India; ⁷Department of Pathology, Aravind Eye Care Hospitals, Madurai, India; ⁸RIA, Department of Laboratory Medicine, Hinduja Hospital, Mumbai, India; ⁹CSI College of Research and Dental Sciences, Madurai; ¹⁰KGS Scan Centre, Madurai, India; ¹¹Department of Endocrinology, Kolling Institute, Royal North Shore Hospital, Sydney, Australia; ¹²Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK;

Key Words: oncogenic osteomalacia, fibroblast growth factor 23

Word Count: 485

Corresponding author: Dr. Anand K Annamalai, Consultant Endocrinologist, Ashwin Speciality Hospital, Madurai, Tamil Nadu, India; Tel: +91-9442282221; E-mail: <u>ak_md2000@yahoo.com</u>

No conflicts of interest

A 36-year-old male presented with a five-year history of progressive generalised body ache, severe bone pain and muscle stiffness which was markedly limiting his activities of daily living. Clinical examination revealed a soft tissue swelling in the lateral aspect of the right knee, together with multiple tender areas in the hips, forearms and legs. Radiological screening revealed bilateral multiple stress fractures involving both upper and lower limbs (Figure 1A).

Laboratory investigation showed normal renal function and serum corrected calcium (8.9 mg/dL; RR 8.5 10.6), but serum phosphorus was significantly low (1.8 mg/dL; RR 2.5-4.4). Serum parathyroid hormone (44.6 pg/mL; RR 14-72) levels were unremarkable, but 25 OH Vitamin D was elevated (107 ng/mL; RR 30-100) on cholecalciferol supplements, with an inappropriately normal 1, 25 (OH)₂ Vitamin D (69.7 pmol/L; RR 47-190) and an inappropriately high urinary phosphorus (1476 mg/day; RR 400-1300). In view of the hypophosphatemia, phosphaturia and an inappropriately normal 1, 25 (OH)₂ Vitamin D, a plasma C-terminal fibroblast growth factor 23 (FGF-23) level was measured which was significantly elevated (294 RU/ml; RR 0-150). Oncogenic osteomalacia was diagnosed and functional imaging with a 68 Ga-DOTANOC-PET revealed focal high tracer uptake (SUVmax = 9.6) in the right tibial condyle (Fig 1B). Structural correlation with CT (Fig 1C) and MRI scan revealed a small 1.8 cm intra osseous lesion in the right postero-lateral tibial condyle. Following excision of the tibial condyle lesion, FGF-23 levels fell dramatically into the low normal range (Day four post surgery: 37 RU/ml). Histopathological examination confirmed a benign phosphaturic mesenchymal cell tumour with positive expression of SSTR2A by immunohistochemistry⁽¹⁾ (Supplementary Figure 2). After a few months the patient reported a rapid and complete resolution of the symptoms, and repeat X-rays at three months demonstrated that the previous fractures had all healed.

Tumour-induced osteomalacia [(TIO) – also referred to as oncogenic osteomalacia] is an underrecognised paraneoplastic syndrome which occurs due to an over production of FGF-23 by small benign soft tissue or bone related mesenchymal tumours.⁽²⁻⁴⁾ The diagnosis can be delayed by decades due to a lack of awareness of the condition.⁽³⁾ TIO can present with generalised body pain,

unexplained fractures, hypophosphatemia and low or inappropriately normal 1,25 (OH)₂ Vitamin D. FGF-23 is a phosphaturic hormone that is normally secreted by the osteoblasts and osteocytes. Elevated FGF-23 levels in TIO prevents phosphate reabsorption by the renal tubules and inhibits 1*a* hydroxylation of 25-hydroxyvitamin D resulting in marked hypophosphatemia. Careful physical examination (from "head to toe") is essential to ensure that all seemingly insignificant soft tissue swellings/lesions are not overlooked. Functional imaging with ⁶⁸Ga-DOTANOC-PET coupled with anatomical imaging (MRI/CT) will allow identification of most lesions. Complete surgical resection of the culprit lesion(s) leads to rapid normalisation of FGF-23 levels, with dramatic resolution of symptoms and subsequent healing of fractures.⁽²⁾ The case and images reported here highlight the importance of a high clinical index of suspicion for TIO in any patient with unexplained myalgia/bone pain and hypophosphatemia.

References

1. Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). *Hum Pathol* 2013;44:2711-8.

2. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. *Am J Surg Pathol* 2004;28:1-30.

3. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. *Endocr Relat Cancer* 2011;18:R53-77.

4. Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH, et al. Tumour-induced osteomalacia. *Nat Rev Dis Primers* 2017;3:17044.

Figure legend:

(A) X-ray of the right forearm showing an insufficiency fracture over the distal $1/3^{rd}$ of the ulna; (B) Whole body Ga-68 DOTANOC PET demonstrating focal tracer uptake within the right tibial condyle (SUVmax = 9.6); (C) Fused Ga-68 DOTANOC PET CT scan of the right knee joint in the lateral plane showing a postero-lateral tibial condyle lesion.

Supplementary Figure legend:

Histological findings of the tibial condyle lesion (A) H&E stain showing diffuse proliferation of bland tumour cells with a haemangiopericytomatous vascular pattern and smudgy matrix [arrow]; (B) area of chondroid differentiation with chondroblasts; (C) Immuno histochemistry (IHC) shows strong positive staining for somatostatin receptor subtype 2 A (SSTR2A).



60



(A) X-ray of the right forearm showing an insufficiency fracture over the distal 1/3rd of the ulna; (B) Whole body Ga-68 DOTANOC PET demonstrating focal tracer uptake within the right tibial condyle (SUVmax = 9.6); (C) Fused Ga-68 DOTANOC PET CT scan of the right knee joint in the lateral plane showing a postero-lateral tibial condyle lesion.



to perezony